Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Comprehensive Overview
Published in the New England Journal of Medicine in 2018, this study asked whether a single infusion of genetically engineered immune cells could produce lasting remissions in children and young adults with leukemia that had already resisted or returned after standard treatment, and whether this complex, personalized therapy could be manufactured and delivered reliably across many countries rather than just one specialized center. Researchers conducted a global, single-arm trial at 25 hospitals in 11 countries, enrolling patients age 3 to 23 with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia, most of whom had already tried several prior therapies and many of whom had relapsed even after a bone marrow transplant. For each of 75 treated patients, their own immune T cells were collected, genetically reprogrammed outside the body to recognize and attack their leukemia cells, and infused back as a single treatment called tisagenlecleucel, a type of CAR T-cell therapy. Researchers tracked how many patients reached remission within three months, how long remissions lasted, and what side effects occurred. As expected from an earlier, smaller single-center study of the same therapy, most patients achieved deep remission after just one infusion, though the treatment carried serious, largely reversible side effects.
Outcomes and Implications
The single most important finding was that 81 percent of treated patients achieved remission within three months of receiving tisagenlecleucel, and every one of these remissions was complete at the molecular level, meaning sensitive testing could not detect any residual leukemia cells. Among all 75 treated patients, an estimated 73 percent remained free of relapse or progression at six months and 50 percent at one year, while overall survival was 90 percent at six months and 76 percent at one year; the engineered T cells remained detectable in some patients' blood up to 20 months after infusion, suggesting durable protection against relapse. These results compare favorably with existing salvage options for this population, such as clofarabine-based chemotherapy, which produces a response in roughly 20 percent of similar patients, and blinatumomab, which produces complete remission in about 39 percent. The therapy carried substantial risks: 77 percent of patients developed cytokine release syndrome, a systemic inflammatory reaction to the activated immune cells, and 40 percent experienced neurologic side effects, though these were managed with supportive care and, in more severe cytokine cases, a drug called tocilizumab. For children and young adults who have exhausted standard treatments and often face a terminal prognosis, this global trial demonstrated that a complex, individualized cellular therapy can be manufactured and delivered safely across international sites rather than one specialized center, supporting its broader adoption for relapsed or treatment-resistant leukemia.